Cite
HARVARD Citation
Li, R. et al. (2022). Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial—a study protocol of clinical trial. BMJ open. 12 (5), p. . [Online].